Compare OC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OC | PODD |
|---|---|---|
| Founded | 1938 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.3B |
| IPO Year | 2006 | 2007 |
| Metric | OC | PODD |
|---|---|---|
| Price | $138.92 | $164.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | $145.27 | ★ $341.48 |
| AVG Volume (30 Days) | 930.2K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | N/A | $24.55 |
| Revenue Next Year | $3.72 | $19.18 |
| P/E Ratio | ★ N/A | $131.25 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $97.53 | $138.79 |
| 52 Week High | $159.91 | $354.88 |
| Indicator | OC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 62.17 |
| Support Level | $136.11 | $141.67 |
| Resistance Level | $144.78 | $205.95 |
| Average True Range (ATR) | 4.15 | 5.66 |
| MACD | -1.17 | 0.64 |
| Stochastic Oscillator | 15.70 | 87.97 |
Owens-Corning Inc is a building products company that offers roofing products and systems, insulation products (hermal and acoustical batts, loose fill insulation, spray foam insulation, wet use chopped strand, etc.), and doors and door systems. The company's reportable segments are: Roofing, Insulation, and Doors. Maximum revenue is generated from the Roofing segment, which manufactures and sells residential roofing shingles, oxidized asphalt materials, roofing components, and composite lumber mainly used in residential construction. This segment also manufactures and sells glass mat and specialty veil materials used in building and construction applications. Geographically, the company generates maximum revenue from the United States, followed by Europe, Asia-Pacific, and other markets.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.